Life Under 50 (Million)
For all the talk about how the consolidation of power into the hands of a tiny group of large hospital buying groups will leave small medical device companies out in the cold, the reality is that many companies are doing just fine, thank you.
You may also be interested in...
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.
Speaking to Scrip, Steven Baert, chief people and organization officer at Novartis, said that a company’s response to coronavirus reveals its real identity and will shape its future.
Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.